Clinical Trial Update: A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating subcutaneous efgartigimod for adults with newly diagnosed generalized myasthenia gravis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: New Onset Generalized Myasthenia Gravis (gMG) | Phase 4 | Status: RECRUITING